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Abstract
Background: Matrix metalloproteinases are proteolytic enzymes responsible for the disorder of extracellular matrix modeling in endometriosis and their 
involvement in the invasion process. The aim of this study was to evaluate the immunohistochemical expression of matrix-metalloproteinases MMP-1, 
MMP-2, MMP-9 and MMP-14 in surgical excision specimens, collected from women with extragenital endometriosis compared to their expression in 
the normal endometrium.
Material and methods: The study included 40 female patients diagnosed with extragenital endometriosis. The used methods consisted in processing the 
specimens by classical histological technique with paraffin inclusion and enzymatic immunohistochemical technique for the detection of metalloproteinases 
MMP-1, MMP-2, MMP-9 and MMP-14.
Results: The expression of matrix metalloproteinases MMP-2, MMP-14 was significant in glandular cells from endometriotic lesions, while MMP-9 was 
evident in both stromal and glandular cells in these lesions. The expression MMP-1 was not present. Normal endometrial tissue showed high reactivity 
for MMP-14 and low reactivity for MMP-2 and MMP-9.
Conclusions: This study reveals some aspects related to the morphological and clinical features of extragenital endometriosis with different locations and 
the correlation between the clinical evolution and some immunohistochemical markers with potential prognosis regarding the aggressiveness of such lesions.
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Introduction
Endometriosis is a comon, benign, inflamatory patho-
logy, represented by the ectopic location of functional endo-
metrial glands and stroma outside the uterine cavity [1, 2]. 
Most sites of implantation involve the ovaries and 
Fallopian tubes, as well as the zones between the uterus and 
the anterior and posterior cul-de-sacs, the uterine ligaments 
and the pelvic wall. In other patients, the endometriotic im-
plants spread beyond the inner genital organs and involve 
other organs in the peritoneal cavity, such as the intestines, 
the bladder or the lower parts of the ureters. Implants of 
ectopic endometrium have also been found in extragenital 
sites, such as surgical scars, the lungs or even the brain [3, 4].
The prevalence rate of symptomatic endometriosis is 
estimated to be 10% with an incidence of about 2-7/1000 
women per year and a further 11% of undiagnosed cases, 
although there are only a few studies with well-estimated 
prevalence and incidence of endometriosis in the gene-
ral population and some suggesting that many, if not all, 
women have endometriosis as a transient phenomenon [5]. 
Endometriosis is associated with a range of symptoms, in-
cluding chronic pelvic pain, dysmenorrhea and infertility, 
all of which can have a strong adverse effect on the physical 
and mental health of the patient. While endometriosis is as-
sumed to be a benign disease from histological standpoint, 
it bears a certain resemblance to malignant tumors due to 
the characteristic of infiltration. While the development 
of endometriosis has been shown to be a complex process 
involving interaction between genetic and environmental 
factors, the etiology and pathology of endometriosis remain 
poorly understood [6].
Numerous theories were proposed to explain etiology of 
endometriosis.
Matrix metalloproteinase (MMP) represents a large 
family zinc-dependent endopeptidases, involved in the 
degradation of the extracellular matrix in the process of en-
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dometrial cell implantation and are classified by their sub-
strate specificity [7, 8]. Several subtypes of MMPs are distin-
guished, depending on their substrate-specificity and local-
ization: collagenases, gelatinases, stromelysins, matrilysins 
and membrane-type metalloproteinases. MMPs play a cru-
cial role in numerous physiological processes, for instance: 
bone remodeling, angiogenesis, inflammation, ovulation 
and embryogenesis. What is more, MMPs are involved in 
cyclic changes of endometrium structure and thickness in 
the steroid hormones concentration levels. MMPs are ex-
pressed in both epithelial and stromal cells. 
Numerous MMPs are additionally involved in many 
pathological processes, such as: fibrosis, weakening of ma-
trix (e.g., in aortic aneurysm or dilated cardiomyopathy) or 
tissue destruction (e.g., cancer invasiveness, also endome-
trial carcinoma invasiveness, and ability to metastasize) [9]. 
Matrix metalloproteinases (MMPs) are essential in or-
chestrating proper physiological functioning of the endo-
metrium; hence, alteration of MMP activities is considered 
as a critical factor for the development of endometriosis. 
MMPs are involved in the cellular event of epithelial-mes-
enchymal transition [10, 11]. 
Objective of the research was to determine the activity 
of MMP-1, MMP-2, MMP-9 and MMP-14 in endometriotic 
lesions of women with endometriosis and compare with 
normal endometrium. 
Material and methods
The study group included 40 female patients diagnosed 
with extragenital endometriosis from 2010–2017, diag-
nosed and surgically treated at the Department of Surgery, 
Obstetrics and Gynecology of Gherghe Paladi Municipal 
Clinical Hospital, Sfantul Arhanghel Mihail Municipal 
Clinical Hospital (Chisinau, the Republic of Moldova) and 
Emergency County Hospital (Craiova, Romania). Endo-
metrial samples of normal proliferative endometrium from 
women who underwent hysterectomy for benign conditions 
were also included for comparison. The investigation was 
performed by using the archival paraffin-embedded tis-
sue blocks corresponding to these cases, preserved at the 
Morphopathology Departments of hospitals. Hematoxylin 
and eosin slides were reviewed by 3 pathologists to confirm 
the diagnosis. Pertinent clinical and demographic informa-
tion was recorded for all study cases.
The research protocols were approved by the Ethics 
Committee of Nicolae Testemitanu State University of Me-
dicine and Pharmacy, based on the patients informed writ-
ten consent for the usage of the biologic material for re-
search.
For immunohistochemistry, we used the paraffin blocks ar-
chived in the Laboratory of Pathology of the same Hospital. 
From these, 4 μm thick seriate sections were cut, which were 
further dewaxed, clarified and hydrated. Then, endogenous 
peroxidase was blocked with hydrogen peroxide (0.3%) for 
15 minutes, at room temperature, and as antigen retrieval, 
we used microwaving for 20 minutes in 0.1 M citrate buf-
fer of pH 6 (with the exception of fibronectin for which we 
used enzymatic retrieval with proteinase K, for 15 minutes, at 
37°C). To avoid the nonspecific binding, the slides were cov-
ered with 2% bovine serum albumin (BSA) for one hour, 
at room temperature. Subsequently, the slides were incubated 
overnight, at 4ºC, with the primary antibodies whose charac-
teristics are presented in Table 1. Then, we used an ampli-
fication based on labeled Strep-tavidin–Biotin 2 (LSAB2) 
enzyme detection system and the correspondent Dako kit 
(Redox, Romania – K0675). 
As chromogen, we used the 3.3’– Diaminobenzidine 
(DAB, Dako, K3468) and the Mayer’s Hematoxylin kit 
(Tunic, Bio-Optica, Romania – M06002) for counter-stain-
ing. As negative internal controls, we used the same slides 
and procedures, but omitting the primary antibody.
The interpretation of the immunohistochemical reac-
tions aimed first of all at highlighting the chromogen at the 
level of the antigenic targets and then at quantifying both 
the intensity of this signal and the proportion of the immu-
noreactive cells. The intensity of the reactions was graded 
using a scale with 4 degrees: 0 – for the absence of reactivity; 
1 – for a light intensity; 2 – for moderate intensity and 3 – 
for high intensity (intense reaction). The reactivity of the in-
flammatory infiltrate (neutrophils, macrophages) was used 
as internal control to evaluate the intensity of these markers, 
this being considered the maximum reactivity. 
A personalized score has been used to evaluate MMP-1, 
MMP-2, MMP-9 and MMP-14 expression: the percentage 
Table 1
Antibodies used in immunohistochemical study





MMP-1 Mouse monoclonal 6A5 Acris AM06648SU-N 1:200
0.1 M Citrate, 
pH 6
Granulation tissue
MMP-2 Mouse monoclonal OTI4A11 OriGene TA806846 1:100
1mM EDTA in 
10mM Tris buffer 
(pH8.5)
Granulation tissue
MMP-9 Mouse monoclonal 5G3 OriGene AM06662SU-N 1:200
0.1 M Citrate, 
pH 6
Granulation tissue 
MMP-14 Mouse monoclonal 113-5B7 OriGene AF8410 1:100 0.1 M Citrate, pH6 Granulation tissue
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of tumoral positive cells (P) and the intensity of staining (I), 
obtaining a P×I final score. 
The proportion of positive cells was also estimated on 
a 4-degree scale: 0 – no positive cells in any microscopic 
field; 1 – <10% of positive cells; 2– between 10-50% of posi-
tive cells and 3 – > 50% of positive cells (the examination 
being done at the x10 objective, respectively on 10 fields). 
The final score (SIHC) was obtained by multiplying the 2 
scores, respectively the qualitative one (intensity) and the 
semiquantitative one (the proportion of reactive cells) and 
was graded as follows: negative (-) for 0; weakly positive (+) 
for 1; moderately positive (++) for 2; and intensely positive 
(+++) for scores 3. In positive immunochemistry, the maxi-
mum score was 9 and minimum – 1. In our score system, we 
established a threshould value of 4, considering a value >4 
as a high score, and a value ≤4 as a low score.  
Results
The patients’ group consisted of 42 women with endo-
metriosis, age range of 21-63 years (median 40). Location 
included: the anterior abdominal wall after caesarean opera-
tion – 20, inguinal hernia – 7, umbilical hernia – 4, perineal 
region – 1, appendix – 4, colon – 5, and ileum – 1case. The 
classical histopatological examination of the general expres-
sion of MMP-1, MMP-2, MMP-9 and MMP-14 revealed a 
diverse variability. For MMP-2, MMP-9, MMP-14 mark-
ers, the reaction positivity was variable not only from one 
case to another but also within each case, the latter being 
characterized by the identification of different areas within 
endometriosis. Consequently, the complex staining patterns 
were homogenous and heterogenous, as a refletion of the 
endometriotic cells equal and variable reaction capacity in 
diferent neighboring territories. We should also note that 
the glandular cell deposit in the center expressed the inves-
tigated molecules compared to a weak expression in the pe-
ripheral focus of endometriosis. 
Our data resulting from the immunohistochemical eval-
uation of MMP-1, MMP-2, MMP-9, MMP-14 respectively, 
based on the quantification of immunopositive tumoral 
cells count and staining intensity, and expressed as individ-
ual scores, are summarized in tab. 2.
The expression of matrix metalloproteinases MMP-2, 
MMP-14 was significant in glandular cells from endome-
triotic lesions, while MMP-9 was evident in both stromal 
and glandular cells in these lesions. The expression MMP-1 
was absent in wall cases of endometriosis and in normal tis-
sue. Normal endometrial tissue showed high reactivity for 
MMP-14 and MMP-9 and low reactivity for MMP-2. 
The reactivity of MMP-2, MMP-9 and MMP-14 metal-
loproteinase in endometriotic lesions was higher than in 
eutopic endometrium. MMP-2 and MMP-9 IHC staining 
was performed, and endometriosis-associated fibrosis and 
lymphocytic infiltrate were evaluated with MMP-1. Nuclear 
staining of MMP-2 for glands and both membranous and 
Table 2
Characteristics of MMP-1, MMP-2, MMP-9 and MMP-14 immunoexpression  
of endometriotic tissue and eutopic endometrium
Location


































































































































0% 0 0 0 0 10% 1 + 1 1 80% 3 +++ 2 6 90% 3 +++ 3 9
Inguinal 
hernia 0% 0 0 0 0 15% 2 + 1 2 60% 2 +++ 2 4 75% 3 +++ 3 9
Umbilical 
hernia 0% 0 0 0 0 10% 1 + 1 1 55% 2 +++ 2 4 60% 3 +++ 3 9
Perineal 









0% 0 0 0 0 10% 1 + 2 2 80% 3 +++ 3 9 90% 3 +++ 3 9
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A    B 
C    D 
E    F 
G    H 
Endometriosis    Normal endometrium 
Fig. 1.  Immunohistochemical reaction interpretation. 
         Endometriosis  normal endometrium
Fig. 1.  Immunohistochemic  eaction interpretation.
Negative reaction for MMP-1 in (A, B), moderate positive reaction for MMP-2 in (C, D), strong positive  
reaction for MMP-9 in (E,F) and MMP-14 in (G, H). IHC, objective 10 × /0.30.
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cytoplasmic staining of MMP-9 for stroma were consi-
dered positive. In cases with intestinal endometriosis stai-
ning was diffuse and intensity was strong (3+), in abdomi-
nal wall endometriosis intensity was moderate (2+) while 
eutopic endometrium staining was diffuse and intensity was 
weak to moderate (1-2+) in all cases. MMP-14 was positive 
and intensity was moderate in both cases. The expression of 
MMP-1 on the examined tissues, was absent in endometrio-
sis and in cases of eutopic tissue. 
Immunohistochemical analysis has demonstrated the 
significant enhance of MMP-9 and MMP-14 expressions in 
endometriosis and in endometrium. The distinctive feature 
of MMP-9 and MMP-14 expression in endometriosis was 
considerable increase of its activity precisely on the border 
of endometriotic lesion and the peritoneum. Elevation of 
MMP-9 and MMP-14 activity was also observed in the stro-
ma of the ectopic endometrium bordering on the under-
lying stroma (fig. 1, E, F, G, H). Enhanced activity of MMP-
9 in the stroma of the ectopic endometrium bordering on 
the underlying stroma was accompanied by the formation 
of macrophage-lymphocyte infiltrates, (fig. 1, E), that evi-
denced the implication of immune cellular components into 
the inflammation zone. Thereby, the obtained research find-
ings allow to suggest, that elevation of MMP-9 activity in 
the sites of endometriotic lesion on the border with the un-
derlying stroma promotes the invasiviness of ectopic endo-
metrium by remodeling of the underlying stroma and infil-
tration of endometrial cells into the peritoneum. Increased 
activity of MMP-2 was observed in stroma of the ectopic 
endometrium bordering on the underlying stroma as well 
(fig. 1, C). The intensified MMP-9 expression in normal 
endometrium was found to prevail in outer membranes of 
endometrial cells (fig. 1, F) while the expression of MMP-14 
was found in intern. Thus, the obtained findings are indica-
tive of the increased MMP-9 and MMP-14 activity in the 
sites of endometriotic lesion.  
Discussion
Endometriosis is one of the most common diseases af-
fecting women of reproductive age. So far, the pathogenesis 
of this disease remains poorly understood. Endometriosis 
is considered a benign disease that nontheless has the pro-
perty of tissue invasion [6].
Metalloproteinases, enzymes that are important for ex-
tracellular matrix turnover, have recently been implicated in 
invasion and development of endometriosis. MMPs appear 
to be overexpressed in endometriotic lesions and contribute 
to establishment of endometrial glands and stroma at ecto-
pic sites [12, 13].
MMP-1 (interstitial or fibroblast collagenase or cola-
genase-1) is the major collagenase able to degrade native 
fibrillar collagens type III, I, and II, at a specific site three 
fourths from the N-terminus. MMP-1 is produced by va-
rious types of cells: fibroblasts, keratinocytes, endothelial 
cells, macrophages, hepatocytes, chondrocytes and asteo-
blasts [14]. 
MMP-2 (gelatinase-A, 72-kDa type IV collagenase) 
cleaves collagen type IV, the major BM constituent, as well 
as degraded collagen and some noncollagenous ECM gly-
coproteins. MMP-2 also degrades native type I collagen. 
TNF-α and β stimulate MMP-2 production and early con-
ceptus (blastocytes) and IFN-τ repress MMP-2 production. 
MMP-2 is expressed by various cell types, including fibro-
blasts, keratinocytes, osteoblasts, and monocytes [15].
MMP-9 (gelatinase-B, 92-kDa gelatinase) cleaves 
N-terminal telopeptide of type I collagen in  an acidic en-
vironment, playing a role in the remodeling of collagenous 
ECM. MMP-9 is produced by normal alveolar macrophages, 
polymorphonuclear leukocytes, osteoclasts, keratinocytes, 
and invading trophoblasts [16].
MMP-14 is a trans-membrane type-1 protease capable 
of degrading different extracellular matrix components, 
such as collagen type I, II, and III as well as fibronectin and 
laminin. The main interest in this enzyme is due to its ability 
to activate different proteases, particularly MMP-2, MMP-9 
and MMP-13 at the cell membrane. MMP-14 plays an im-
portant role in angiogenesis and is expressed by dermal fi-
broblasts, and osteoclasts [21].
The presence and role of MMPs in endometriosis is 
unquestionable, however the exact sequence of events is 
unclear. It remains obscure, whether changes in their ac-
tivity occur primarily in uterine cavity, that due to cellular 
memory allows endometrium fragments implantation into 
peritoneum, or whether specific conditions in peritoneal 
cavity (inflammation or other immunological processes) 
change MMPs activity in endometrial cells discarded from 
uterus during retrograde menstruation. Moreover, some 
balance switches in matrix remodeling in eutopic endome-
trium can be periodic or temporal and vanish just after le-
sion constitution on ectopic site. What is more, changes of 
MMPs, demonstrated in uterine endometrium at women 
with endometriosis may also occur after implantation of ec-
topic lesions, under the influence of processes taking place 
in peritoneum. Solution of this riddle seems to be hard to 
find, as it would require prospective study based on endo-
metriotic biopsies in asymptomatic population of women 
and long-term observation for endometriosis onset [9, 17].
In the literature, there is no agreement on differences 
in the expression of MMP-2 among endometriotic tissues 
and eutopic endometrium at women affected or unaffected 
by endometriosis. However, endometriotic tissues seem to 
express more MMP-2 than eutopic endometrium [18-21].
Conclusions
The MMP-9 and MMP-14 activity significant elevation 
is established on ectopic endometrium of women with en-
dometriosis. Study of MMP-1, MMP-2, MMP-9 and MMP-
14 activities in endometriotic lesions at women with endo-
metriosis is perspective for further investigation in order 
to determine a possible role of matrix metalloproteinases 
in the development of invasiviness process in case of extra-
genital endometriosis.
11
oriGiNal  research E. Cazacu et al. Moldovan Medical Journal. October 2020;63(4):6-11
References
1. Cazacu E, Zota E, Mărgăritescu C. Procesul de tranziție epitelio-
mezenchimală în endometrioza extragenitală [Epithelial-mesenchymal 
transition process in extragenital endometriosis]. Sănătate Publică, 
Economie și Menagement în Medicină [Public Health Econ Manag 
Med] (Chisinau). 2019(2/80):66-70. Romanian.
2. Brătilă E, Ionescu OM, Badiu DC, Berceanu C, Vlădescu S, Pop DM, 
Mehedinţu C. Umbilical hernia masking primary umbilical endome-
triosis–case report endometriosis. Rom J Morphol Embryol. 2016;57(2 
Suppl):825-829.
3. Istrate-Ofițeru AM, Pirici D, Niculescu M, Berceanu C, Berceanu S, Voicu 
NL, Piringă GD, Roșu GC, Iovan L, Căpitănescu RG, Dițescu D, Sava A, 
Mogoantă L, Neacșu A. Clinical, morphological and immunohistochemi-
cal survey in different types of endometriosis. Rom J Morphol Embryol. 
2018;59(4):1133-1153.
4. Schorge JO, Schaefer JI, et al. Endometriosis. In: Schorge JO, et al., edi-
tors. Williams gynecology. New York: McGraw Hill Medical; 2008. p. 
225-43.
5. Lagana AS, Garzon S, Götte M, Vigano P, Franchi M, Ghezzi F and Martin 
Dan C. The pathogenesis of endometriosis: Molecular and cell biology 
insights. Int J Mol Sci. 2019;20(22):5615. doi: 10.3390/ijms20225615.
6. Lingli Xin, Qingxiang Hou, Qi Xiong and Xiaoping Ding. Association 
between matrix metalloproteinase-2 and matrix metalloproteinase-9 
polymorphisms and endometriosis: a systematic review and meta-
analysis. Biomed Rep. 2015;3(4):559-565. doi: 10.3892/br.2015.447. 
7. Avădanei R, Căruntu ID, Amălinei C, Lozneanu L, Balan R, Grigoraș A, 
Apostol DC, Giușca SE. High variability in MMP2/TIMP2 and MMP9/
TIMP1 expression in secondary liver tumors. Rom J Morphol Embryol. 
2013;54(3):479-485.
8. Madjid TH, Ardiansyah DF, Permadi W, Hernowo B. Expression of 
matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 
in endometriosis menstrual blood. Diagnostics (Basel). 2020;10(6):364. 
doi: 10.3390/diagnostics10060364.
9. Balkowiec M, Radoslaw BM, Wlodarski PK. The bimodal role of matrix 
metalloproteinases and their inhibitors in etiology and pathogenesis 
of endometriosis (Review). Mol Med Rep. 2018;18(3):3123-3136. doi: 
10.389/mmr.2018.9303.
10. Sayantan J, Kasturi Ch, Amlan KR, Pramathes D, Snehasikta S. 
Regulation of matrix metalloproteinase–2 activity by COCS-2-PGE2-
pAKT Axis promotes angiogenesis in endometriosis. PLoS One. 
2016;11(10):e0163540. doi: 10.1371/journal.pone.0163540.
11. Rîvneac V, Gudumac V, Rîvneac E, Pretula R, Grecikina E. Localizarea 
electron-histochimică a colagenazei în ficat [Electrochemical localization 
of collagenase in the liver]. In: [Scientific Annals of Nicolae Testemitanu 
State University of Medicine and Pharmacy. 9th ed. Vol. 1]. Chisinau: 
Medicina; 2008. p. 53-55. Romanian.
12. Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda 
K, Yamaguchi H, Akise D, Hung YC, Ueki M. Surviving gene expression 
in endometriosis. J Clin Endocrinol Metab. 2002;87(7):3452-3459. doi: 
10.1210/jcem.87.7.8682.
13. Ye H, He Y, Wang J, Song T, Lan Z, Zhao Y, Xi M. Effect of matrix metalo-
proteinase promoter polymorphisms on endometriosis and adenomyosis 
risk: evidence from a meta-analysis. J Genet. 2016;95(3):611-619. doi: 
10,1007/s12041-016-0675-5.
14. Amălinei C, Căruntu ID, Bălan RA. Biology of metalloproteinases. Rom 
J Morphol Embriol. 2007;48(4):323-334.
15. Patterson ML, Atkinson SJ, Knăuper V, Murphy G. Specific collagenolysis 
by gelatinase A, MMP-2, is determined by the hemopexin domain and 
not the fibronectin-like domain. FEBS Letters. 2001;503(2-3):158-162. 
doi: 10.1016/s0014-5793(01)02723-5.
16. Hashizume K. Analysis of utero-placental-specific molecules and their 
functions during implantation and placentation in the bovine. J Reprod 
Dev. 2007;53(1):1-11. doi: 10.1262/jrd.18123.
17. Sotnikova NY, Antsiferova YS, Posiseeva LV, Shishkov DN, Posiseev 
DV, Filippova ES. Mechanisms regulating invasiveness and growth of 
endometriosis lesions in rat experimental model and in humans. Fertil 
Steril. 2010;93(8):2701-2705. doi: 10.1016/j.fertnstert.2009.11.024.
18. Gaide Chevronnay HP, Selvais C, Emonard H, Galant C, Marbaix E, 
Henriet P. Regulation of matrix metalloproteinases activity studied in 
human endometrium as a paradigm of cyclic tissue breakdown and re-
generation. Biochim Biophys Acta. 2012;1824(1):146-156. doi: 10.1016/j.
bbapap.2011.09.003.
19. Di Carlo C, Bonifacio M, Tommaselli GA, Bifulco G, Guerra G, 
Nappi C. Metalloproteinases, vascular endothelial growth factor, and 
angiopoietin 1 and 2 in eutopic and ectopic endometrium. Fertil Steril. 
2009;91(6):2315-2323. doi: 10.1016/j.fertnstert.2008.03.079.
20. Chung HW, Lee JY, Moon HS, Hur SE, Park MH, Wen Y, Polan ML. Ma-
trix metalloproteinase-2, membranous type 1 matrix metalloproteinase, 
and tissue inhibitor of metalloproteinase-2 expression in ectopic and 
eutopic endometrium. Fertil Steril. 2002;78(4):787-795. doi: 10.1016/
s0015-0282(02)03322-8.
21. Uzan C, Cortez A, Dufournet C, Fauvet R, Siffroi JP, Daraï E. Eutopic 
endometrium and peritoneal, ovarian and bowel endometriotic tissues 
express a different profile of matrix metalloproteinases-2, -3 and -11, 
and of tissue inhibitor metalloproteinases-1 and -2. Virchows Arch. 
2004;445(6):603-609. doi: 10.1007/s00428-004-1117-y.
Authors’ ORCID iDs and academic degrees 
Eugeniu Cazacu, MD, PhD Applicant – https://orcid.org/0000-0003-2893-6401. 
Eremei Zota, MD, PhD, Associate Professor – https://orcid.org/0000-0003-1365-2633.
Claudiu Margaritescu, MD, PhD, Professor – https://orcid.org/0000-0002-4937-5589.
Radu Niguleanu, MD, PhD, Associate Professor – https://orcid.org/0000-0002-6797-6142.
Ruslan Pretula, MD, PhD, Associate Professor – https://orcid.org/0000-0002-4785-3647.
Authors’ contribution
EC designed the trial, interpreted the data, wrote the manuscript, revised and approved the final version of the manuscript;
EZ conducted and conceptualized the project; CM conducted the laboratory work, revised the manuscript critically; RP collected material 
and performed the laboratory work; RN collected material and performed the laboratory work. All the authors revised the final version of the 
manuscript.
Funding 
The study was supported by Nicolae Testemitanu State University of Medicine and Pharmacy. No grants were involved in supporting this work. 
The authors are independent and take responsibility for the integrity of the data and accuracy of the data analysis.
Ethics approval and consent to participate 
The study protocol was approved by the Research Ethics Committee of Nicolae Testemitanu State University of Medicine and Pharmacy of the 
Republic of Moldova (proceeding No 63/58, 16.03.2017). Written informed consent was obtained from all participants in the study. 
Conflict of Interests 
There is no known conflict of interests and financial or non-financial support associated with this publication.
